Abstract

Objective:To investigate peripheral blood T lymphocyte subsetsCD3 +,CD4 +,CD8+, NK cells changes in the diffuse large B cell lymphoma patients before chemotherapy,the second chemotherapy cycle and the fourth chemotherapy cycle,and analyse the relationship between the results and treatment,for the further clinical work. Methods: Collect the 47 patients venous blood diagnosed DLBCL by pathology in our hospital. CD3+、CD4+、CD4+/CD8+、NK cells are determined in flow cytometric. Analyse the results statistically significant difference before treatment,the second chemotherapy cycle and the fourth chemotherapy cycle compared with 50 healthy control person, analyse the results of different treatment effect statistically significant difference in different chemotherapy cycles. Results:The level of CD3+、CD4+、CD4+/CD8+、NK cells with DLBCL patients before chemotherapy is lower than healthy controls (P<0.05), and the level of CD8 + cells is higher than the healthy controls (P<0.05);The level of CD3+、CD4+、CD4+/CD8+ cells had significant difference between the second and the fourth chemotherapy cycle in DLBCL patients(P<0.05). The level of CD3+、CD4+、CD8+、CD4+/CD8+、NK cells had significant difference between the fourth chemotherapy cycle DLBCL patients and the DLBCL patients before chemotherapy(P<0.05). The level of CD3+、CD4+、CD4+/ CD8+cells with partial remission the fourth chemotherapy cycle DLBCL patients is lower than the complete remission the fourth chemotherapy cycle DLBCL patients(P<0.05). The level of CD3+、CD4+、CD8+、CD4+/CD8+、NK cells had significant difference between the complete remission the fourth chemotherapy cycle DLBCL patients and the DLBCL patients before chemotherapy(P<0.05). The level of CD3+、CD4+、CD4+/CD8+、NK cells with the complete remission after the fourth chemotherapy cycle DLBCL patients is higher than the DLBCL patients before chemotherapy(P<0.05). The level of CD3+、CD4+ cells with the complete remission after the fourth chemotherapy cycle is higher than the complete remission after the second chemotherapy cycle in DLBCL patients (P<0.05). Conclusion:The DLBCL patients exist immunosuppression in the body before chemo- therapy.Peripheral T lymphocyte subsets and NK cells can be used as a good reflect of the cellular immune function in DLBCL patients.Clinical parameters can be used for the immune function monitoring.Providing guidance for the treatment options.